2026. Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s730. DOI:https://doi.org/10.25251/7mx6d484.